Q3 2025 Exelixis Inc Earnings Call Transcript
Key Points
- Exelixis Inc (EXEL) reported strong financial performance with a 14% year-over-year increase in US cabozantinib net product revenues, reaching $543 million in Q3 2025.
- The company is experiencing robust demand for cabozantinib, maintaining its leadership position as the top TKI for renal cell carcinoma (RCC) and achieving significant growth in the first-line segment.
- Zanzalintinib is advancing rapidly as a promising oncology franchise opportunity, with seven ongoing and soon-to-start pivotal trials, including positive results from the STELLAR-303 trial in colorectal cancer (CRC).
- Exelixis Inc (EXEL) has a strong balance sheet with approximately $1.6 billion in cash and marketable securities, allowing for continued R&D investment and a $750 million share repurchase authorization.
- The company is expanding its gastrointestinal (GI) sales team to accelerate growth in the cabozantinib neuroendocrine tumor (NET) indication and prepare for the potential launch of zanzalintinib in CRC.
- Exelixis Inc (EXEL) faces market competition and regulatory challenges, which could impact the commercial success of its products and future growth opportunities.
- The company experienced higher deductions from revenue related to 340B discounts, affecting the gross-to-net ratio for the cabozantinib franchise.
- There is uncertainty regarding the approval of the STELLAR-303 trial results for zanzalintinib in CRC, as regulatory nuances and competitive dynamics in the CRC market could pose challenges.
- Exelixis Inc (EXEL) incurred a $19.8 million restructuring charge in Q3 2025, contributing to an increase in operating expenses.
- The company is navigating a fragmented CRC market, which presents both opportunities and challenges in gaining market share with new treatment options.
Good day, ladies and gentlemen, and welcome to the Exelixis' third-quarter 2025 financial results conference call. My name is Cherie, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Thank you, Cherie, and thank you all for joining us for the Exelixis' third-quarter 2025 financial results conference call.
Joining me on today call are Mike Morrissey, our President and CEO; and Chris Senner, our Chief Financial Officer; Dana Aftab, our Executive Vice President of Research and Development; and PJ Haley, our Executive Vice President of Commercial, who will review our progress for the third-quarter 2025 ended October 3, 2025.
During the call today, we will refer to financial measures not calculated according to generally accepted
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
